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Summary
Background:  Critically  ill  patients  lack  capacity  for  decisions  about  research  participation.
Consent  to  enrol  these  patients  in  studies  is  typically  obtained  from  substitute  decision-makers.
Objective:  To  present  strategies  that  may  optimise  the  process  of  obtaining  informed  consent
from substitute  decision-makers  for  participation  of  critically  ill  patients  in  trials.  We  use  exam-
ples from  a  randomised  trial  of  heparin  thromboprophylaxis  in  the  intensive  care  unit  (PROTECT,
clinicaltrials.gov  NCT00182143).Studies;
Substitute
decision-makers
Methods:  3764  patients  were  randomised,  with  an  informed  consent  rate  of  82%;  90%  of  consents
were obtained  from  substitute  decision-makers.  North  American  PROTECT  research  coordi-
nators attended  three  meetings  to  discuss  enrolment:  (1)  Trial  start-up  (January  2006);  (2)
Near trial  closure  (January  2010);  and  (3)  Post-publication  (April  2011).  Data  were  derived  from
slide presentations,  ﬁeld  notes  from  break-out  groups  and  plenary  discussions,  then  analysed
inductively.
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Results:  We  derived  three  phases  for  the  informed  consent  process:  (1)  Preparation  for  the
Consent  Encounter;  (2)  The  Consent  Encounter;  and  (3)  Follow-up  to  the  Consent  Encounter.
Speciﬁc strategies  emerged  for  each  phase:  Phase  1  (four  strategies);  Phase  2  (six  strategies);
and Phase  3  (three  strategies).
Conclusion: We  identiﬁed  13  strategies  that  may  improve  the  process  of  obtaining  informed
consent from  substitute  decision-makers  and  be  generalisable  to  other  settings  and  studies.
©  2013  The  Authors.  Published  by  Elsevier  Ltd.  
Implications  for  clinical  practice
• Informed  consent  for  research  is  an  ongoing  process.
• Optimising  informed  consent  for  research  participation  is  a  multi-phase  process  that  starts  before  a  study  is  imple-
mented  and  involves  the  inter-professional  ICU  clinical  team.
• Implementation  of  these  13  strategies  may  help  to  improve  the  integrity  of  the  informed  consent  process,  minimise
SDM  decisional  burden  and  maximise  timely  enrolment  of  eligible  patients  into  clinical  studies  in  the  ICU.
Introduction
Clinical  research  in  the  intensive  care  unit  (ICU)  is  essential
to improve  the  outcomes  of  critical  illness  (Luce  et  al.,  2004;
McRae and  Weijer,  2002;  Yarborough,  1993).  Timely  comple-
tion of  randomised  trials  and  the  generalisability  of  study
results are  contingent  upon  recruitment  of  the  majority  of
eligible patients  (Wade  et  al.,  2009;  Watson  and  Torgerson,
2006). While  deferred  or  waived  consent  models  have  been
employed in  ICU  trials  of  urgent  interventions  (Annane
et al.,  2002;  NICE-SUGAR  Investigators  et  al.,  2009;  Roberts
et al.,  2004),  interventional  trials  typically  require  a priori
informed consent.  Most  critically  ill  patients  are  incapable
of research  decision-making  (Fan  et  al.,  2008),  such  that
substitute decision-makers  (SDMs)  are  typically  approached
to consider  research  opportunities  on  their  behalf  (Arnold
and Kellum,  2003).  SDM  consent  to  research  is  the  preferred
enrolment approach  of  ICU  survivors  (Chenaud  et  al.,  2009;
Scales et  al.,  2009),  ICU  family  members  (Barrett  et  al.,
2012; Chenaud  et  al.,  2009;  Perner  et  al.,  2010),  research
ethics board  (REBs)  (Duffett  et  al.,  2011;  Gong  et  al.,  2010)
and the  public  (Burns  et  al.,  2011).
Ethical  and  procedural  guidelines  require  research  con-
sent to  be  informed,  voluntary,  documented  and  ongoing
(Canadian Institutes  of  Health  Research,  Natural  Sciences
and Engineering  Research  Council  of  Canada,  and  Social
Sciences and  Humanities  Research  Council  of  Canada,
2010; International  Conference  on  Harmonisation,  1997;
National Commission  for  the  Protection  of  Human  Subjects
of Biomedical  and  Behavioral  Research,  1979;  Nuremburg
code, 1996;  World  Medical  Association,  1997).  Researchers
are obligated  to  disclose  risks  and  beneﬁts  of  participa-
tion to  decision-makers,  and  to  ensure  understanding  of
the research  purpose  and  procedures.  Making  a  decision
about research  participation  in  the  ICU  may  be  difﬁcult  for
SDMs for  several  reasons.  First,  enrolment  is  often  time-
sensitive, sometimes  even  requiring  a  decision  within  hours
2013;  Ranieri  et  al.,  2012).  Second,  most  SDMs  are  unaware
of patient  wishes  regarding  research  (Chenaud  et  al.,  2009;
Ciroldi et  al.,  2007;  Coppolino  and  Ackerson,  2001)  and
must balance  their  understanding  of  patient  values  with
knowing how  trial  interventions  may  cause  more  harm  than
good, or  introduce  risk  without  beneﬁt.  Third,  compre-
hension of  SDMs  regarding  medical  issues  and  research  in
the ICU  is  limited  (Azoulay  and  Pochard,  2002;  Rodriguez
et al.,  2008).  Finally,  SDMs  are  anxious,  and  involvement  in
research decision-making  may  increase  psychological  bur-
den (Wendler  and  Rid,  2011)  or  induce  post-traumatic  stress
(Azoulay et  al.,  2005).  In  this  unique  context,  research
coordinators approach  SDMs,  inviting  their  consideration  of
research opportunities  for  critically  ill  patients.
SDMs  may  agree  to,  or  decline,  a  request  for  a  criti-
cally ill  patient  to  participate  in  research.  High  rates  of
refusal can  decrease  the  generalisability  of  trial  results
if non-consenting  participants  are  systematically  different
than consenting  participants,  even  if  the  desired  sample  size
is achieved  (Chertow  et  al.,  2003;  Crowley  et  al.,  2008).
In observational  research,  it  has  been  suggested  that  the
requirement for  informed  consent  can  lead  to  biased  results
due to  the  systematic  exclusion  of  some  individuals  (Gershon
and Tu,  2008;  Tu  et  al.,  2004).  Recruitment  rates  vary
across studies;  however,  rates  can  also  differ  among  centres
recruiting patients  into  the  same  trial  (Smith  et  al.,  2012)
underscoring how  several  factors  may  inﬂuence  enrolment,
just one  of  which  is  the  informed  consent  process  (Table  1).
Although systematic  reviews  have  addressed  patient  recruit-
ment strategies  outside  the  ICU  setting  (Caldwell  et  al.,
2010; Mapstone  et  al.,  2007;  Watson  and  Torgerson,  2006),
literature is  sparse  on  how  to  improve  the  informed  consent
process for  research  involving  critically  ill  patients.
The  objective  of  this  report  is  to  present  strategies
that may  optimise  the  process  of  obtaining  informed  con-
sent from  SDMs  for  participation  of  critically  ill  patients
in randomised  trials.  To  illustrate  some  strategies,  we
Open access under CC BY-NC-ND license.(Burns et  al.,  2009).  For  example,  in  two  recently  published
international randomized  controlled  trials,  the  eligibility
criteria dictated  that  patients  be  enrolled  within  24  hours
of demonstrating  signs  of  septic  shock  (Guntupalli  et  al.,
u
b
h
ise the  example  of  PROTECT  (the  Prophylaxis  for  Throm-
oEmbolism in  Critical  Care  Trial)  an  international  trial  of
eparin thromboprophylaxis  for  medical-surgical  critically
ll patients  (clinicaltrials.gov  NCT00182143).
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Table  1  Factors  potentially  inﬂuencing  enrolment  into  a
clinical  trial.
(1)  Non-modiﬁable  factors
Case-mix  of  patients
Number  of  beds
Availability  of  substitute  decision  makers
(2) Modiﬁable  factors
Research  culture
Support  of  the  clinical  team
Presence  of  research  coordinators
Interpretation  of  the  inclusion  and  exclusion  criteria
Research  coordinator  workload
Approval  of  telephone  consent  procedures
Coenrolment  procedures
Consent  rate
In this table we outline the non-modiﬁable and modiﬁable fac-
tors that can inﬂuence enrolment of patients into a clinical trial.
This article is focused on strategies to facilitate the last poten-
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The  PROTECT  Trial  Manager  collated  plenary  discussion
points  across  meetings.
Research  ethics  of  trial
The  PROTECT  protocol  and  consent  forms  were  approved
by  each  centre’s  Research  Ethics  Board.  The  consent  form
outlined  the  study  purpose,  procedures,  possible  risks  and
beneﬁts  and  ranged  from  2  to  10  pages  across  centres.
Written  informed  consent  was  obtained  from  SDMs  or
patients.  The  overall  PROTECT  consent  rate  was  82%  (range
50—100%)  across  participating  centres;  90%  of  the  consents
were  obtained  from  SDMs.
Analysis
The  foundational  data  for  our  analysis  were  derived  from
the  initial  slide  presentations  and  expanded  through  critical
discussion  at  each  of  the  three  research  coordinator  meet-
ings.  The  slide  presentations  were  created  by  the  principal
investigator  (DJC)  and  the  senior  coordinators  of  the  trial
(EM,  NZ)  and  included  points  on  general  ethical  principles  for
research  consent  in  the  ICU,  speciﬁc  consent  requirements
for  PROTECT,  and  suggestions  for  how  to  discuss  consent
for  PROTECT  with  eligible  patients  and/or  their  designates.
Field  notes  from  the  break-out  groups  and  discussion  points
from  the  plenary  sessions  were  analysed  inductively  by  four
of  the  authors  (OMS,  EM,  NZ,  DJC).  This  led  to  recognition  of
three  distinct  temporal  phases  of  the  informed  consent  pro-
cess:  Preparation  for  the  Consent  Encounter,  The  Consent
Encounter  and  Follow-up  to  the  Consent  Encounter.  Within
these  phases,  we  identiﬁed  13  speciﬁc  strategies  to  optimize
the  informed  consent  process  (Table  2).
Table  2  Strategies  for  informed  consent  from  substitute
decision-makers  in  an  ICU  trial.
Phase  1:  Preparation  for  the  Consent  Encounter
(1)  Brand  the  trial  with  key  messages
(2)  Train  local  research  personnel
(3) Promote  a  culture  of  research
(4) Be  familiar  with  the  patient  and  family  dynamics
Phase  2:  The  Consent  Encounter
(5)  Involve  the  bedside  staff
(6) Introduce  the  idea  of  research  in  a  professional,
positive  manner
(7)  Present  the  facts  about  the  research  problem  and  the
outcomes
(8) Explain  all  research-related  activities
(9)  Convey  risks  and  beneﬁts  transparently
(10) Describe  alternatives  to  participation  and  support
the  consent  decision
Phase  3:  Follow-up  to  the  Consent  Encounter
(11)  Document  the  consent  process
(12)  Provide  thanks  and  ongoing  study  updates  to  all
stakeholders
(13) Follow-up  with  the  patient  to  ensure  ongoing  consent
In this ﬁgure, we present three phases to the informed con-tially modiﬁable factor, the informed consent process.
ethods
ROTECT  was  a  concealed,  randomised,  stratiﬁed,  blinded
hromboprophylaxis  trial  of  low-molecular  weight  heparin
ersus  unfractionated  heparin.  Patients  were  considered
or  enrolment  if  they  were  ≥18  years  of  age,  weighed
45  kilograms,  and  were  expected  to  remain  in  ICU
72  hours.  The  primary  outcome  was  proximal  leg  deep
ein  thrombosis.  Secondary  outcomes  were  venous  throm-
oembolism  at  any  site,  the  composite  outcome  of  venous
hromboembolism  or  death,  major  bleeding,  minor  bleeding
nd  heparin-induced  thrombocytopenia.  This  trial  was  com-
leted  on  schedule,  recruiting  patients  over  4  years  from
ay  2006  to  June  2010  in  67  ICUs  in  6  countries.  Methods  and
esults  of  the  pilot  trial  and  full  trial  are  available  elsewhere
Cook  et  al.,  2005;  PROTECT  Investigators,  2011).
Novice  and  experienced  North  American  research  coordi-
ators  involved  in  PROTECT  attended  three  study  meetings:
anuary  2006  (before  recruitment  began),  January  2010  (in
he  ﬁnal  year  of  recruitment)  and  April  2011  (after  publi-
ation  of  the  main  results).  In  total,  98  persons  attended
hese  meetings  (77  persons  attended  1  meeting,  15  persons
ttended  2  meetings  and  6  persons  attended  all  3  meet-
ngs).  Overall,  71  persons  participated  in  their  capacity  as  a
esearch  coordinator.
At  each  of  these  multipurpose  meetings  of  North  Amer-
can  collaborators  funded  by  the  Canadian  Institutes  of
ealth  Research,  one  session  focused  on  screening,  consent-
ng  and  enrolling  patients.  The  objective  of  these  sessions
as  to  develop  a  clear,  concise,  ethical  approach  to  procur-
ng  consent  for  enrolling  ICU  patients  into  studies.  These
essions  were  interactive,  including  an  oral  presentation
acilitated  by  power-point  slides  and  group  discussion.  At
he  ﬁrst  meeting,  a  role-playing  video  on  obtaining  consent
or  PROTECT  was  shown.  At  the  second  and  third  meet-
ngs,  attendees  formed  small  break-out  groups  for  additional
rainstorming.  Each  small  group  had  a  scribe  who  made  ﬁeld
otes;  each  group  had  a  rapporteur  who  verbally  summa-
ized  discussion  points  in  a  plenary  session  of  all  attendees.
sent process, and the associated 13 strategies that may help
to optimise the informed consent process when talking to SDMs.
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Results
Phase  1:  Preparation  for  the  Consent  Encounter
In  all  sessions,  research  coordinators  identiﬁed  the  need
for  both  the  trial  Methods  Center  and  participating  sites  to
engage  in  preparatory  work  prior  to  commencing  recruit-
ment.  Four  speciﬁc  strategies  were  considered  essential  to
successful  preparation.
Strategy  #1:  brand  the  trial  with  key  messages
To  facilitate  recruitment  at  the  local  sites,  it  is  helpful  for
the  study  Methods  Center  to  craft  and  disseminate  key  mes-
sages  to  be  highlighted  in  educational  sessions  with  bedside
staff.  These  can  also  be  touchstones  for  consent  discussions
with  SDMs.  An  example  from  the  PROTECT  Methods  Center
is  the  ‘top  10’  talking  points  for  PROTECT  outlined  in  Fig.  1.
Strategy  #2:  train  local  research  personnel
Before  soliciting  consent  from  an  SDM,  research  coordinators
need  to  be  adequately  prepared  to  explain  the  study  and
answer  questions.  Training  exercises  can  include:  attend-
ing  the  study  start-up  meeting;  preparing  a  consent  script
including  lay  terms  for  complex  concepts;  practicing  the
consent  dialogue  with  a  colleague  and  lay  person;  solicit-
ing  input  on  techniques  from  an  experienced  coordinator;
and  sharing  of  both  successful  and  non-successful  strategies
with  colleagues.  Practice  exercises  are  especially  important
for  novice  coordinators  and  experienced  coordinators  new
to  the  ICU.
Strategy  #3:  promote  a  culture  of  research
Engagement  of  ICU  bedside  staff  in  the  trial  was  identi-
ﬁed  as  key  to  successful  recruitment.  Consider  study  launch
events;  research  updates  as  a  standing  agenda  item  during
ICU  staff  meetings;  posting  study  information  on  staff  com-
munication  boards;  and  study  newsletters.  The  visibility  and
accessibility  of  research  personnel  to  the  front  line  staff  is
Figure  1  Top  10  PROTECT  Talking  Points.  In  this  ﬁgure,  we
outline key  points  that  served  as  touchstones  for  increasing
familiarity  with  PROTECT.  These  ‘Top  10  Talking  Points’  were
useful  to  describe  some  features  of  the  trial  during  initial
bedside  staff  education,  and  during  initial  informed  consent
dialogue.
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rucial.  Research  coordinators  can  promote  a  research  cul-
ure  throughout  the  trial  by  providing  staff  with  recruitment
rogress  and  soliciting  feedback  on  addressing  recruitment
hallenges.  For  the  public,  posters  and  brochures  in  waiting
ooms  can  be  used.  Printed  family  information  can  explain
he  importance  of  research  in  general  and  details  about  spe-
iﬁc  studies,  as  permitted  by  local  Research  Ethics  Boards.
nformation  should  be  clear,  simple  and  devoid  of  jargon.
osters  should  be  eye-catching,  presenting  research  as  an
ntegral  part  of  hospital  activities,  but  clearly  optional.
trategy  #4:  be  familiar  with  the  patient  and  family
ynamics
efore  approaching  the  SDM,  conﬁrm  patient  eligibility  for
he  study  by  reviewing  the  trial  inclusion  and  exclusion  crite-
ia  and  the  patient’s  medical  history.  Discuss  the  assessment
f  patient  eligibility  with  the  ICU  staff  and  investigator.  For
afety  reasons,  when  suitable,  conﬁrm  with  the  physician
hat  there  are  no  medical  contraindications  to  the  patient’s
articipation.  Clarify  the  identity  of  the  SDM  with  the  med-
cal  staff,  which  is  not  always  clearly  documented.  Ask  the
edside  nurse  if  the  SDM  is  available  and  approachable.
nquire  about  familial  issues  requiring  sensitivity.  Ask  about
iming  the  consent  encounter  according  to  the  SDM’s  visita-
ion  schedule  and  around  medical  updates.  Before  meeting
he  family,  review  the  consent  document  to  ensure  comfort
ith  the  content,  and  to  be  able  to  easily  direct  the  SDM
o  speciﬁc  sections  of  the  form,  so  that  study  information  is
ortrayed  consistently,  verbally  and  in  writing.
hase  2:  The  Consent  Encounter
esearch  coordinators  identiﬁed  six  strategies  to  optimise
he  actual  consent  encounter  with  the  SDM.  The  principles  of
thical  research  conduct  are  embedded  in  these  strategies.
hese  also  reﬂect  professional  behaviours  of  the  research
oordinator,  teamwork  and  communication  techniques.
trategy  #5:  involve  the  bedside  staff
he  bedside  nurse  and  physician  should  be  aware  that  the
atient  is  a  candidate  for  research  participation  and  why.
eview  the  study  procedures,  risks  and  beneﬁts  with  the
taff  before  approaching  the  SDM.  Knowledgeable  bedside
taff  can  introduce  research  coordinators  to  the  family,
aving  established  that  the  family  is  interested  in  hearing
bout  the  study,  particularly  in  those  centres  requesting  that
omeone  from  the  circle  of  care  be  involved  in  approaching
he  family.  If  appropriate  or  required  by  local  policies,  ask
 member  of  the  ICU  team  to  introduce  you  to  the  family.  If
uitable,  invite  the  bedside  nurse  or  physician  to  be  present
uring  family  discussions.  After  the  consent  encounter,  bed-
ide  staff  can  also  assist  by  answering  family  questions  and
einforcing  information  shared  by  the  research  coordinator.
trategy  #6:  introduce  the  idea  of  research  in  a
rofessional,  positive  manner
rofessionally  state  your  name,  professional  designation  and
ole  in  the  ICU  to  the  SDM.  Explain  that  the  ICU  physician
nvited  you  to  present  an  opportunity  for  the  patient  to
articipate  in  a  study.  Explain  that  the  SDM  is  being  asked
o  consider  consent  because  the  patient  is  not  capable  of
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ecision-making.  If  possible,  provide  a  quiet  and  private
lace  for  discussion.  However,  if  the  SDM  prefers  the  dis-
ussion  to  occur  at  the  bedside,  proceed  according  to  their
ishes.  Inquire  as  to  who  else  the  SDM  would  like  present.  If
ultiple  people  are  present,  acknowledge  each  individual.
ake  a  seat  to  converse  at  eye-level.  Ensure  that  phones
nd  pagers  are  turned  off  or  on  a  silent  mode  to  avoid  inter-
uptions.  Focus  the  conversation  on  the  patient  and  their
ndividual  suitability  for  the  trial.  Use  clear  and  simple  terms
o  explain  the  concept  of  research  in  general.  Highlight  the
ospital  and  ICU’s  commitment  to  improving  patient  care
hrough  research.  Be  prepared  for  myriad  reactions  ranging
rom  interest  to  disinterest,  and  enthusiasm  to  scepticism.
ecognise  that  research  may  be  a  foreign  concept.  Be  pre-
ared  to  respond  supportively  if  people  become  emotional.
cknowledge  that  decision-making  can  be  burdensome.
trategy  #7:  present  the  facts  about  the  research
roblem  and  the  outcomes
se  simple  facts  to  convey  the  extent  of  the  problem  that
he  research  is  designed  to  address.  In  PROTECT,  coordi-
ators  informed  SDMs  of  the  prevalence  of  blood  clots  in
ritically  ill  patients  using  published  statistics,  indicating
hat  up  to  3—5%  of  ICU  patients  are  admitted  with  a pre-
xisting  but  typically  unrecognized  DVT,  and  up  to  8—10%
f  ICU  patients  develop  a  DVT  while  in  ICU.  Personalise  the
iscussion  by  highlighting  the  particular  suitability  of  the
atient  for  the  study.  In  PROTECT,  coordinators  cited  immo-
ility,  sedation  and  central  venous  catheters  as  risk  factors
or  developing  DVTs.  Provide  decision-makers  with  a  clear
ationale  for  the  study  interventions  and  explain  the  uncer-
ainty  amongst  clinicians  about  which  of  the  interventions
s  best,  hence  the  need  for  the  trial.  In  PROTECT,  research
oordinators  educated  families  about  the  potential  for  leg
VTs  to  be  undetected  and  to  travel  to  the  lungs  in  the
orm  of  pulmonary  emboli,  which  can  result  in  serious  conse-
uences  such  as  prolonged  mechanical  ventilation  or  death.
trategy  #8:  explain  all  research-related  activities
t  is  important  to  be  clear  about  what  is  ‘standard  of  care’
nd  what  comprises  research.  If  the  study  involves  random-
zation,  explain  the  number  of  study  arms  and  process  of
andomisation  in  simple  terms.  If  the  study  involves  blinding,
xplain  who  will  be  blinded  to  what,  and  why.  For  example,
n  PROTECT,  patients  had  an  equal  chance  (i.e.  50/50  or
ﬂip  of  a  coin’)  of  receiving  unfractionated  heparin  or  low
olecular  weight  heparin.  Patients,  families,  ICU  staff  and
esearch  staff  were  all  blinded;  only  the  research  pharma-
ist  preparing  the  study  medication  was  aware  of  what  drug
he  patient  was  receiving.  Research  coordinators  explained
hat  the  blinding  method  was  the  best  scientiﬁc  way  to
ccurately  evaluate  the  development  of  clots  or  bleeding.
f  the  study  involves  diagnostic  tests,  explain  when  these
ests  will  occur  and  what  will  happen  with  the  results.  In
ROTECT,  bilateral  leg  compression  ultrasounds  were  per-
ormed  at  study  entry  and  twice  weekly  thereafter  until  ICU
ischarge.  Ultrasound  results  were  shared  with  the  bedside
linical  staff  to  ensure  timely  treatment,  if  indicated.  Tell
amilies  how  often  and  for  how  long  monitoring  and  data
ollection  will  continue.  Assure  them  of  the  privacy  and
onﬁdentiality  of  data  collected.
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trategy  #9:  convey  risks  and  beneﬁts  transparently
e  clear  with  families  about  the  types  and  likelihood  of
dverse  outcomes  associated  with  the  study.  Clarify  whether
r  not  the  risks  of  participation  are  greater  than  what
ould  be  expected  as  part  of  standard  care.  Be  frank  about
hether  or  not  there  are  any  direct  beneﬁts  to  the  par-
icipants  or  whether  beneﬁts  pertain  solely  to  generation
f  knowledge  to  help  future  patients,  to  avoid  therapeutic
isconception.  Because  routine  screening  ultrasounds  are
ot  part  of  standard  care,  bedside  compression  ultrasounds
ere  considered  a  beneﬁcial  surveillance  as  part  of  partici-
ation  in  PROTECT,  which  allowed  early  detection  of  DVT  if
t  was  not  clinically  suspected.  SDMs  learned  that  critically
ll  patients  rarely  develop  classic  signs  or  symptoms  of  DVT
ecause  they  are  supine  and  receiving  sedation  and  analge-
ia;  therefore,  ultrasound  is  generally  necessary  to  detect
VT  in  the  ICU.
trategy  #10:  describe  alternatives  to  participation  and
upport  the  consent  decision
einforce  the  voluntary  nature  of  consent  and  inform  the
amily  that  the  patient  will  receive  high  quality  care  regard-
ess  of  whether  they  participate.  Remind  the  family  that
onsent  may  be  withdrawn  at  any  stage  without  con-
equence.  Ask  the  family  if  they  have  any  unanswered
uestions  and  whether  they  would  like  to  speak  to  the  local
nvestigator  or  bedside  physician.  Acknowledge  that  a  lot
f  information  has  been  presented  about  potentially  for-
ign  concepts.  Suggest  that  the  SDM  reﬂect  on  what  the
atient  would  say  if  they  were  capable.  Offer  the  family
ufﬁcient  time  to  think  and  talk  about  the  study  privately,
ut  be  clear  about  any  time  restrictions  on  recruitment.  If
dditional  time  is  requested,  speciﬁcally  plan  to  re-connect
o  obtain  their  decision.  Thank  the  family  for  their  consid-
ration,  whether  they  ultimately  agree  or  decline.
hase  3:  Follow-up  to  the  Consent  Encounter
fter  the  consent  encounter  and  a  decision  about  partici-
ation  has  been  rendered,  the  consent  process  continues.
esearch  coordinators  described  three  additional  strategies
ollowing  the  actual  consent  decision.
trategy  #11:  document  the  consent  process
f  the  SDM  has  declined  the  study,  communicate  this  to  the
CU  team  and  thank  them  for  any  help  they  provided.  If  the
DM  has  agreed  to  the  study,  ask  them  to  sign,  date  and
ime  the  consent  form.  Place  the  original  consent  form  in
he  study  ﬁle  and  provide  the  SDM  with  a  copy  of  the  signed
orm.  If  suitable  as  per  local  standard  operating  procedures,
nsert  a copy  of  the  consent  form  in  the  patient’s  medi-
al  chart.  Write  a  note  in  the  patient’s  chart  to  document
he  consent  discussion  and  enrolment  of  the  patient  in  the
tudy.  Remember  to  include  the  name  of  the  SDM  and  their
elationship  to  the  patient;  the  name  of  witnesses  to  the  dis-
ussion;  highlights  of  the  consent  discussion;  and  date  and
ime  that  consent  was  received.  Provide  a  brief  summary
f  the  study  activities  in  your  note  for  the  bedside  clinical
eam.  Research  coordinators  suggested  a  standardized  tem-
late  as  a  source  document  to  record  the  consent  encounter,
ith  space  to  insert  patient-speciﬁc  details.
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Strategy  #12:  provide  thanks  and  ongoing  study  updates
to  all  stakeholders
As  the  study  unfolds,  to  ensure  that  all  parties  feel  included
and  appreciated  in  the  research  process,  acknowledge  each
person’s  contribution  verbally,  in  writing,  or  both  if  appro-
priate.  Thank  the  SDM  and  patient  (if  capable)  for  the
opportunity  to  include  the  patient  in  the  study.  Acknowl-
edge  the  ICU  team  members  who  facilitated  the  consent
encounter,  and  those  who  assist  with  study  procedures.
Remember  contributions  of  staff  outside  the  ICU  such  as
those  in  the  research  pharmacy,  laboratory  and  diagnostic
imaging,  expressing  your  gratitude  frequently.  Provide  fam-
ily  members  with  updates  about  the  patient’s  progress  in
the  study  as  it  evolves.  It  is  important  for  them  to  know
that  research  staff  members  are  continuing  to  follow  the
patient’s  course  in  the  ICU.  Ongoing  contact  with  research
personnel  may  facilitate  a  positive  research  experience.
Ensure  that  the  ICU  bedside  team  is  aware  of  the  patient’s
progress  in  the  study  by  ﬂagging  pertinent  diagnostic  test
results.  In  PROTECT,  research  coordinators  provided  updates
to  the  ICU  team  on  ultrasound  results,  and  trends  in  coagu-
lation  tests  and  platelet  counts,  to  alert  them  to  potential
problems  such  as  heparin-induced  thrombocytopenia.
Strategy  #13:  follow-up  with  the  patient  to  ensure
ongoing  consent
In  keeping  with  the  context  of  this  report,  although  the
majority  of  consents  for  ICU  research  studies  are  obtained
from  SDMs,  participants  should  be  assessed  regularly  for
research  decision-making  capacity  over  the  study  to  the
extent  that  this  is  possible  to  achieve.  If  the  patient  demon-
strates  capacity  prior  to  completion  of  study  activities,
discuss  consent  with  the  patient  directly.  Ensuring  that  the
patient  is  informed  about  enrolment  and  has  the  opportu-
nity  to  make  a  decision  about  continued  participation  is  an
important  aspect  of  patient  autonomy  in  the  ongoing  con-
sent  process.
Discussion
Through  soliciting  and  documenting  the  consenting  experi-
ences  of  North  American  research  coordinators  who  worked
on  the  PROTECT  trial,  we  collated  13  strategies  to  opti-
mise  a  3-phase  informed  consent  process  when  approaching
SDMs  regarding  the  enrolment  of  critically  ill  patients  into
randomised  trials.  The  strategies  suggested  by  research
coordinators  both  reinforce  requirements  for  informed  con-
sent  outlined  in  existing  legislation  and/or  guidelines,  and
also  highlight  additional  processes  that  may  enhance  the
integrity  of  the  consent  process.
Strategies  outlined  in  Phase  1,  Preparation  for  the  Con-
sent  Encounter,  represent  suggestions  to  prepare  both  ICU
and  research  personnel  to  begin  a  new  study,  starting  with
training,  review  of  materials  and  key  messages  from  the
study  Methods  Center.  The  importance  of  multi-modal  train-
ing  for  research  coordinators  is  noted  by  others  (Felsen
et  al.,  2010).  Difﬁculty  explaining  study  details  in  simple
terms  can  negatively  impact  on  recruitment,  as  identiﬁed
through  qualitative  analysis  of  screening  logs,  interviews  of
study  personnel  and  audio-recordings  in  a  urology—oncology
trial  (Paramasivan  et  al.,  2011).  Creating  and  sharing  a
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study  tool  box’  which  includes  simpliﬁed  study  messages
or  research  personnel,  clinicians  and  SDMs  may  increase
ecruitment,  as  suggested  in  a  survey  of  252  oncology  inves-
igators  and  coordinators  (Ulrich  et  al.,  2010).  The  PROTECT
ethods  Center  provided  consent  tools  and  training  to  North
merican  research  coordinators  in  the  form  of  workshops,
haring  of  the  Top  10  Talking  Points  about  PROTECT  to  help
ith  initial  dialogue  and  key  messages  (Fig.  1).  The  Methods
enter  developed  slides  on  rigorous,  transparent  approaches
o  obtaining  informed  consent.  A  role-playing  video  of  the
onsent  encounter  was  also  created  to  demonstrate  ways
o  respond  to  various  SDM  reactions  and  questions.  Simula-
ion  training,  role-playing  exercises,  videos  and  workshops
ave  been  shown  to  enhance  communication  in  the  ICU
Berkenstadt  et  al.,  2008)  and  improve  recruitment,  based
n  reports  from  114  publically  funded  trials  in  the  United
ingdom  (McDonald  et  al.,  2006).
In  the  clinical  setting,  bedside  staff  may  have  limited
nowledge  of,  or  minimal  interest  in  research,  or  harbour
oncerns  about  it,  which  can  contribute  to  recruitment  chal-
enges  (Alt-White  and  Pranulis,  2006;  Dale  et  al.,  2010;
iegand  et  al.,  2008).  Researchers  should  identify  any
edside  staff  worries  and  address  them  pre-emptively.
ngagement  of  staff  champions,  staff  in-services  and  post-
ng  study  advertisements  can  generate  research  support
nd  help  to  discover  and  resolve  staff  concerns.  Research
oordinators  should  be  cognisant  of  local  ICU  culture  and
ailor  communication  and  education  strategies  accordingly
o  promote  a  favourable  research  environment  (Chlan  et  al.,
009).  Ideally,  bedside  staff  members  are  aware  of  research
nitiatives  for  which  their  patients  may  be  eligible;  however,
taff  should  at  least  understand  the  fundamentals  of  stud-
es  in  which  their  patients  are  enrolled,  particularly  if  they
ave  key  role(s)  such  as  study  drug  administration.
Research  coordinators  recommended  promoting  a  cul-
ure  of  research  to  families  through  printed  materials  in
CU  admission  packages,  display  of  illustrative  posters  and
esearch  brochures  where  families  congregate,  such  as  the
CU  waiting  room  (Fig.  2).  Family  members  may  not  initially
e  aware  that  research  is  ongoing  in  the  ICU  as  demonstrated
n  a  recent  Canadian  survey  (Dale  et  al.,  2010).  The  major-
ty  of  ICU  family  members  report  a  desire  to  receive  written
nformation  about  research  (Soltner  et  al.,  2009).
Within  Phase  2,  the  Consent  Encounter,  research  coor-
inators  had  multiple  suggestions  to  facilitate  interactions
ith  SDMs  about  patient  participation  in  research.  Profess-
onalism  and  conﬁdence  of  the  research  coordinator  are
ey,  as  these  attributes  shape  the  SDM’s  ﬁrst  impression
f  research.  In  some  settings,  individuals  report  that  their
ecision  to  consent  to  research  was  positively  inﬂuenced  by
ompetent,  personable  and  experienced  research  person-
el  (Felsen  et  al.,  2010).  In  the  ICU,  research  coordinators
hould  express  empathy,  recognising  the  burden  of  having
 family  member  or  close  friend  who  is  critically  ill,  and
cknowledging  SDM  uncertainty  inherent  in  research  deci-
ion  making  (Rose  and  Kasner,  2011;  Sugarman  et  al.,  2001).
 common  reason  for  SDM  refusal  of  research  in  the  ICU  is
tress  (Grap  and  Munro,  2003;  Mehta  et  al.,  2012).An  SDM’s  uncertainty  regarding  research  decision-making
ay  be  related  to  lack  of  familiarity  with  critical  illness,
nd  lack  of  familiarity  with  the  patient’s  values  regarding
esearch  (Azoulay  et  al.,  2001;  Rodriguez  et  al.,  2008).  SDMs
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Figure  2  Example  of  research  brochure  or  poster.  In  this  ﬁg-
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familiar.  Additional  explanation  may  be  required  for  tri-re, we  present  an  example  of  a  research  brochure  which  may
elp to  enhance  the  institutional  research  culture.
ay  sometimes  equate  a  request  for  consent  as  permission
o  use  the  patient  as  a  ‘guinea  pig’  (Morgenweck,  2003).
esearch  coordinators  must  spend  sufﬁcient  time  with  SDMs
o  provide  them  with  clear  information  about  the  purpose,
isks,  beneﬁts  and  voluntariness  of  the  study  and  to  assess
heir  comprehension  (Chenaud  et  al.,  2007).  Clarity  about
he  direct  possible  beneﬁts  to  the  patient,  as  compared  to
he  beneﬁts  to  future  patients,  is  essential.  Careful  dia-
ogue  is  required  to  avoid  therapeutic  misconception,  or  the
istaken  belief  that  the  primary  intent  of  the  study  is  to
reat  the  patient  as  opposed  to  answer  a  research  question
Appelbaum  et  al.,  1982).  SDMs  in  the  ICU  may  be  partic-
larly  susceptible  to  therapeutic  misconception,  given  the
igh  morbidity  and  mortality  associated  with  critical  illness
Flanagan  et  al.,  2011;  Mehta  et  al.,  2012)  and  possible  mis-
nderstandings  about  research  (Bigatello  et  al.,  2003).  An
ffective  way  to  increase  understanding  of  the  consent  pro-
ess  is  through  prolonged  periodic  engagement  (Flory  and
manuel,  2004).  SDMs  may  not  understand  key  research  con-
epts,  such  as  blinding  and  randomisation  (Snowdon  et  al.,
997),  so  research  coordinators  should  individualise  consent
ncounters,  providing  information  in  different  formats  if
ecessary  (Wade  et  al.,  2009).
SDMs  should  be  encouraged  to  reﬂect  on  whether  the
atient  would  be  agreeable  to  participate  if  they  could
ecide  themselves  (Berger,  2011).  Lack  of  SDM  conﬁdence
egarding  what  the  patient  would  decide  can  induce  deci-
ional  burden  (Wendler  and  Rid,  2011).  The  majority  of  ICU
DMs  report  the  desire  to  engage  others,  including  the  ICU
a
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hysician,  in  decision-making  about  research  (Barrett  et  al.,
012;  Mehta  et  al.,  2012).  Cultural  factors  may  inﬂuence  the
ecision-making  process.  To  avoid  errant  assumptions,  be
ware  that  in  some  cultures,  decision  making  may  be  based
n  family  consensus  or  deferred  to  male  family  members
Braun  et  al.,  2008;  Charles  et  al.,  2006;  Kwak  and  Haley,
005;  Shrank  et  al.,  2005).
In  closing,  ask  SDMs  if  they  have  any  remaining  questions
r  concerns  or  if  they  desire  to  speak  with  the  study  inves-
igator,  then  provide  sufﬁcient  time  for  decision-making
Crowley  et  al.,  2008;  Ross  et  al.,  1999;  Wright  et  al.,  2004).
esearch  coordinators  should  thank  the  SDM  for  considering
he  study  and  support  them,  whatever  the  outcome.  Lack  of
upport  in  decision-making  appears  to  increase  the  risk  for
dverse  psychological  outcomes  for  ICU  SDMs  (Siegel  et  al.,
008).
In  Phase  3,  Follow-up  to  the  Consent  Encounter,  the
ngoing  nature  of  consent  is  underscored  by  several  key
ctivities.  Patients  and  families  involved  in  emergency
esearch  report  a  desire  for  more  information  after  enrol-
ent  (Kamarainen  et  al.,  2012).  The  need  to  engage  in
ngoing  assessment  of  patient  capacity  for  involvement  in
ecision-making  is  crucial  (Bigatello  et  al.,  2003;  Chenaud
t  al.,  2007);  however,  only  a  minority  of  patients  pass
ormal  capacity  screens  both  during  their  ICU  stay  and
efore  hospital  discharge  which  can  preclude  the  ability  of
he  research  coordinator  to  obtain  ﬁrst-party  consent  (Fan
t  al.,  2008;  Scales  et  al.,  2009).  Furthermore,  there  is  no
lear  guidance  in  the  literature,  or  in  existing  ethical  frame-
orks,  as  to  how  long  the  mandate  for  re-consent  should
pply.  In  Canada,  re-consenting  practices  are  variable  and
he  time-frame  for  re-consenting  tends  to  be  dictated  by
ocal  REB  practices.  Following  initial  SDM  consent,  concerns
bout  the  potential  for  the  ‘re-consenting  process’  with
atients  to  introduce  bias  as  a  result  of  post-randomisation
ithdrawals  (Truog,  2007),  especially  in  unblinded  ran-
omised  trials,  is  the  subject  of  active  research  (Duffett
t  al.,  2011).
We  encourage  principal  and  local  investigators  to  monitor
onsent  rates  and  provide  feedback  and  support  to  partici-
ating  centres  throughout  a  trial.  In  PROTECT,  the  informed
onsent  rate  was  82%;  however,  rates  ranged  from  50  to  100%
cross  sites.  We  previously  documented  factors  that  were
ndependently  associated  with  high  consent  rates  (Smith
t  al.,  2012)  including:  research  coordinator  experience;  ICU
ize  (<15  beds  compared  to  ≥15  beds);  and  the  availability  of
1  full-time  research  personnel.  We  also  found  that  consent
ates  were  lower  in  centres  afﬁliated  with  formal  research
onsortia  compared  to  those  that  were  not.  Consent  rates
ere  highest  during  the  PROTECT  Pilot  Trial;  lowest  during
he  initiation  of  the  full  trial;  and  increased  each  year  of
ecruitment.  To  complement  the  foregoing  analyses  on  the
atterns  and  predictors  of  consent  rates,  we  developed  this
eport.
This  report  is  limited  in  that  we  elicited  consent  strate-
ies  in  the  context  of  a  low-risk  trial  testing  two  widely
vailable  drugs  used  to  prevent  blood  clots.  The  problem
f  blood  clots  is  one  with  which  the  public  is  generallyls  of  less  familiar  conditions,  novel  drugs  or  devices  that
onfer  higher  risk,  or  trials  involving  more  urgent  inter-
entions.  We  focused  on  the  consent  process  with  SDMs
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rather  than  seeking  initial  consent  from  adult  patients,
since  the  latter  is  infrequently  possible  in  the  ICU.  We
did  not  discuss  telephone  consent,  which  was  rare  in  PRO-
TECT  and  not  approved  by  most  Research  Ethics  Boards.
Our  focus  was  the  process  of  informed  consent  rather  than
all  aspects  of  participant  recruitment  or  reasons  for  non-
enrolment,  such  as  physician  refusals,  missed  patients,  or
the  unavailability  of  SDMs.  Readers  are  referred  elsewhere
for  literature  underscoring  the  importance  of  a  clear  con-
sent  form  and  the  inﬂuence  of  consent  form  length  on
understanding  (Beardsley  et  al.,  2007;  Jefford  and  Moore,
2008;  Silverman  et  al.,  2005;  Stunkel  et  al.,  2010).  Although
PROTECT  was  an  international  trial,  the  strategies  pre-
sented  herein  represent  the  views  and  experiences  of  North
American  research  coordinators.  Jurisdictional  differences
and  legal  requirements  may  decrease  the  applicability  of
some  of  our  suggested  strategies;  however,  strategies  7—10
reﬂect,  in  general,  internationally  accepted  standards  for
informed  consent  in  human  subjects  research  that  should  be
considered  obligatory,  not  optional  (Canadian  Institutes  of
Health  Research,  Natural  Sciences  and  Engineering  Research
Council  of  Canada,  and  Social  Sciences  and  Humanities
Research  Council  of  Canada,  2010;  International  Conference
on  Harmonisation,  1997;  National  Commission  for  the
Protection  of  Human  Subjects  of  Biomedical  and  Behavioral
Research,  1979;  Nuremburg  code,  1996;  Rischbieth  et  al.,
2005;  World  Medical  Association,  1997).
While  some  randomised  trials  have  examined  recruitment
and  consent  strategies  for  patient  participation  in  research
(Caldwell  et  al.,  2010;  Mapstone  et  al.,  2007;  Watson
and  Torgerson,  2006),  no  published  study  has  examined
the  acceptability  and  effectiveness  of  different  strate-
gies  targeting  SDMs  in  the  ICU.  Additional  quantitative  and
qualitative  investigations  are  needed  to  better  understand
factors  positively  and  negatively  inﬂuencing  recruitment
into  ICU  trials.  Two  recent  Canadian  observational  stud-
ies  suggest  that  altruism  and  potential  patient  beneﬁt  may
motivate  SDMs  to  provide  consent  while  fear,  anxiety  and
risk-aversion  may  prompt  refusal  (Burns  et  al.,  2010;  Mehta
et  al.,  2012).  The  role  of  patient  decision  aids  to  enhance
understanding  and  improve  research  decision-making  is  cur-
rently  being  assessed  (Brehaut  et  al.,  2010).  The  utility  of
research  decision  aids  in  the  ICU  is  worthy  of  investiga-
tion,  given  signals  that  not  all  SDMs  desire  an  active  role
in  decision-making  (Anderson  et  al.,  2009;  Azoulay  et  al.,
2004;  Barrett  et  al.,  2012;  Heyland  et  al.,  2003)  and  given
that  SDM  research  decision-making  appears  to  increase  the
risk  for  post-traumatic  stress  (Pochard  et  al.,  2005).  Testing
the  impact  of  multiple  rather  than  single  strategies  would
be  instructive.
Conclusion
In  summary,  we  have  presented  13  strategies  to  enhance
the  process  of  informed  consent  by  SDMs  for  randomised
trials  in  critically  ill  adults,  based  on  the  experiences  of  a
large  group  of  diverse  North  American  research  coordinators
during  an  international  trial  of  heparin  thromboprophylaxis.
We  encourage  research  coordinators  to  comply  with  their
own  local  requirements  for  informed  consent,  which  may
vary  by  jurisdiction  within  countries  and  across  countries.
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e  advocate  practicing  approaches  to  informed  consent,
nd  establishing  or  engaging  in  research  networks  that
ncourage  sharing  tips  with  colleagues.  We  hope  that  this
hird-phase  interpretation  of  the  process  of  informed  con-
ent  from  SDMs  may  help  to  improve  the  integrity  of  the
nformed  consent  process,  minimise  SDM  decisional  burden,
nd  maximise  timely  enrolment  of  eligible  patients  into
linical  studies.  Further  research  on  the  impact  of  these
trategies  to  achieve  these  aims  is  warranted.
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